A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

NCT06422663 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-04-08

No results posted yet for this study

Summary

This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.

Conditions

  • Moderate-to-Severe Asthma

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2025-03-13
Completion
2025-03-13

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06422663 on ClinicalTrials.gov